Month: February 2021

– G1’s COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March –– Launch Underway, including Medical Affairs, Promotional, and Educational Activities to Introduce COSELA to Oncologists and Oncology Nurses and Build Awareness of Myelosuppression –– On-track to Initiate Three Additional Clinical Trials in 1H2021 to Assess the Potential Myeloprotection and/or Anti-Tumor Efficacy Benefit of COSELA in Multiple Cancers –– Management to Host Webcast and Conference Call today at 4:30 PM ET –RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update...

MITCHEL FIELD, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) today announced the selection of its high performance oscillators and microwave frequency generation units for ultimate application on a key US government satellite system. This first phase contract is valued at approximately $17M, with a four year period of performance. A Phase 2 follow-on contract for additional flight units is anticipated.FEI CEO, Stan Sloane, commented, “We are extremely pleased that our flagship satellite products have been selected for another critical military program. FEI continues to be the go-to provider of technically advanced, high-stability oscillators, as well as RF and microwave sources for space. This reflects continuing customer confidence in our ability to deliver critical components...

— NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020— Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 MillionBOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the quarter and year ended December 31, 2020.

ROCHESTER, Mich., Feb. 24, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the fourth quarter and full year ended December 31, 2020. Quarterly and full year comparisons are to the same year-ago period.Financial HighlightsRevenue in the fourth quarter of 2020 increased 123% to a record $16.4 million, with the full year of 2020 up 76% to a record $43.3 million.Gross profit in the fourth quarter of 2020 increased 92% to $8.6 million.GAAP net income totaled $1.4 million or $0.08 per diluted share in the fourth quarter.Non-GAAP net income in the fourth quarter totaled $2.7 million or $0.16 per diluted share (see definition of this non-GAAP measure and reconciliation to GAAP, below).Cash and cash equivalents...

JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of common shares of the Company. For each common share purchased, an investor will also receive a warrant to purchase a common share of the Company. The Company intends to use the net proceeds from the offering primarily to fund research and development expenses for its clinical and preclinical research and development activities and for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.Guggenheim...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2020.Recent Highlights:Achieved total revenue of $58.6 million for the three months ended December 31, 2020, increasing 64% over prior year fourth quarterDelivered record full year revenue of $192.2 million, an increase of 51% compared with full year 2019 revenueProvided over 25,000 patient results in the fourth quarter and approximately 79,000 patient results in 2020Generated GAAP net loss of $3.5 million, non-GAAP net income of $4.3 million, and positive...

NORTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) — CPS Technologies Corporation (NASDAQ:CPSH) today announced revenues of $20.9 million and an operating profit of $914 thousand for the year ended December 26, 2020. This compares with revenues of $21.5 million and an operating loss of $597 thousand for the year ended December 28, 2019.For the quarter ending December 26, 2020, revenues were $4.2 million with an operating loss of $291 thousand. For the quarter ending December 28, 2019, revenues were $5.4 million with an operating profit of $367 thousand.Grant Bennett, President and CEO, said, “2020 was unique. As the year progressed, customer demand for our existing, higher volume products, particularly baseplates for traction power modules, declined each quarter because of the increasing effects of Covid-19.On the other hand, demand...

Daix (France), February 24, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will participate at three upcoming investor conferences in March 2021.The event details are as follows:Conference n°1: Credit Suisse Virtual 2021 London Global Healthcare ConferenceEvent type: One-on-one investor meetingsDate: Tuesday-Thursday, March 2-4, 2021Format: Virtual eventConference n°2: H.C. Wainwright Virtual Global Life Sciences ConferenceEvent type: Corporate presentation, fireside chat, one-on-one investor meetingsDate: Tuesday,...

Daix (France), le 24 février 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique (NASH), des mucopolysaccharidoses (MPS) et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui que Frédéric Cren, Président-directeur général et cofondateur d’Inventiva, participera à trois conférences investisseurs au cours du mois de mars 2021.Les détails des événements sont les suivants :Conférence n°1 : « Credit Suisse Virtual 2021 London Global Healthcare Conference »Type d’événement : Rendez-vous investisseursDate : Mardi-jeudi, 2-4 mars 2021Format : Evénement virtuelConférence n°2 : « H.C. Wainwright Virtual Global Life Sciences Conference »Type...

MENLO PARK, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the “Company”), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the closing of its previously announced private placement of 2,564,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,564,000 shares of common stock at a combined purchase price of $4.55 per share and accompanying warrant. The warrants are exercisable immediately at an exercise price of $5.00 per share and expire five years from the date of issuance. Gross proceeds were approximately $11.7 million, before deducting placement agent fees and other offering...